Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy

Luis A Carvajal; Ulrich Steidl

doi:10.1016/j.stem.2016.06.005

Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy

Cell Stem Cell. 2016 Jul 7;19(1):6-8. doi: 10.1016/j.stem.2016.06.005.

Authors

Luis A Carvajal¹, Ulrich Steidl²

Affiliations

¹ Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
² Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Medicine (Oncology), Albert Einstein College of Medicine-Montefiore Medical Center, Bronx, NY 10467, USA; Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Institute for Stem Cell Research and Regenerative Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA. Electronic address: [email protected].

PMID: 27392220
DOI: 10.1016/j.stem.2016.06.005

Abstract

Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.

Publication types

Comment

MeSH terms

Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
Leukemia, Myeloid, Acute
Neoplastic Stem Cells*